Overview

Gender

male

Investor Type

Investment Partner

Amir Nashat is a Managing Partner in Polaris’ Boston office. Amir joined Polaris in 2002 and focuses on investments in healthcare.

Amir currently represents Polaris as a Member of the Board of Directors at AgBiome, aTyr Pharmaceuticals (NASDAQ: LIFE), BIND Therapeutics (NASDAQ: BIND), Fate Therapeutics (NASDAQ: FATE), Metacrine, Promedior Pharmaceuticals, Scholar Rock, Selecta Biosciences, and Syros Pharmaceuticals.

Additionally, Amir has served as a Member of the Board of Directors at Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Living Proof, Pervasis Therapeutics (Shire Pharmaceuticals), Receptos (Celgene) and Sun Catalytix (Lockheed Martin).

At Living Proof and Sun Catalytix, Amir served as the company’s initial Chief Executive Officer.

Amir serves on the Partners Innovation Fund and is a Catalyst of the Deshpande Center for Technological Innovation at MIT.

Amir previously served on the Board of the New England Venture Capital Association.

Amir has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”

Prior to joining Polaris, Amir completed his Ph.D. as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his M.S. degree and B.S. degree in Materials Science and Mechanical Engineering at the University of California, Berkeley.